Skip to main content

EPA and Huntington's chorea: treatment and associated cerebral changes

Huntington's disease (Huntington's chorea) is an autosomal dominant disease of the human brain caused by an unstable expansion of CAG trinucleotide triplet repeats in the huntingtin gene at 4p16.3; the CAG repeats are transcribed and translated into polyglutamine expansion (polyQ) stretches, and the length of the repeats correlates inversely with age of onset. Huntington's disease is characterized by motor dysfunction, with chorea and incoordination occurring relatively early and dystonia, rigidity and bradykinesia becoming more prominent with time; death usually occurs within 15-25 years of onset of motor symptomatology. The key neuropathological change is neuronal degeneration, particularly in the striatum. The scientific background is given for why fatty acids may play an important role in Huntington's disease. Evidence is then presented from a randomized double-blind placebo-controlled to show that ultra-pure ethyl-eicosapentaenoic acid (ethyl-EPA), a semi-synthetic, ethyl ester of eicosapentaenoic acid, is associated with clinical improvement in motor functioning in Huntington's disease. The likely mechanisms of this beneficial action are then described. Finally, the results are detailed of a further recent study to determine the extent to which ethyl-EPA might reduce the rate of progress of cerebral atrophy. High-resolution cerebral magnetic resonance imaging scans were acquired at baseline, six months and one year in up to 34 patients with stage I or II Huntington's disease who took part in the trial of ethyl-EPA. For each subject and each pair of structural images, the two-timepoint brain volume change was calculated in a double-blind manner.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Basant K Puri.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Puri, B.K. EPA and Huntington's chorea: treatment and associated cerebral changes. Ann Gen Psychiatry 9, S27 (2010). https://doi.org/10.1186/1744-859X-9-S1-S27

Download citation

Keywords

  • Dystonia
  • Magnetic Resonance Imaging Scan
  • Autosomal Dominant Disease
  • Cerebral Atrophy
  • Neuropathological Change